Search

Your search keyword '"Pitcher, Bethany"' showing total 115 results
Start Over Author "Pitcher, Bethany"
115 results on '"Pitcher, Bethany"'

1. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid TumorsEntrectinib in NTRK+ Solid Tumors: Updated Efficacy/Safety

Author

Demetri, George D, De Braud, Filippo, Drilon, Alexander, Siena, Salvatore, Patel, Manish R, Cho, Byoung Chul, Liu, Stephen V, Ahn, Myung-Ju, Chiu, Chao-Hua, Lin, Jessica J, Goto, Koichi, Lee, Jeeyun, Bazhenova, Lyudmila, John, Thomas, Fakih, Marwan, Chawla, Sant P, Dziadziuszko, Rafal, Seto, Takashi, Heinzmann, Sebastian, Pitcher, Bethany, Chen, David, Wilson, Timothy R, and Rolfo, Christian

Subjects
Cancer, Clinical Trials and Supportive Activities, Brain Disorders, Neurosciences, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Benzamides, Carcinoma, Non-Small-Cell Lung, Child, Humans, Indazoles, Lung Neoplasms, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeEntrectinib potently inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, and previously induced deep [objective response rate (ORR) 57.4%] and durable [median duration of response (DoR) 10.4 months] responses in adults with NTRK fusion-positive solid tumors from three phase I/II trials. This article expands prior reports with additional patients and longer follow-up.Patients and methodsPatients with locally advanced/metastatic NTRK fusion-positive solid tumors and ≥12 months' follow-up were included. Primary endpoints were ORR and DoR by blinded independent central review (BICR); secondary endpoints included progression-free survival (PFS), intracranial efficacy, and safety. The safety-evaluable populations included all patients who had received ≥1 entrectinib dose.ResultsAt clinical cut-off (August 31, 2020), the efficacy-evaluable population comprised 121 adults with 14 tumor types and ≥30 histologies. Median follow-up was 25.8 months; 61.2% of patients had a complete (n = 19) or partial response (n = 55). Median DoR was 20.0 months [95% confidence interval (CI), 13.0-38.2]; median PFS was 13.8 months (95% CI, 10.1-19.9). In 11 patients with BICR-assessed measurable central nervous system (CNS) disease, intracranial ORR was 63.6% (95% CI, 30.8-89.1) and median intracranial DoR was 22.1 (95% CI, 7.4-not estimable) months. The safety profile of entrectinib in adults and pediatric patients was aligned with previous reports. Most treatment-related adverse events (TRAEs) were grade 1/2 and manageable/reversible with dose modifications. TRAE-related discontinuations occurred in 8.3% of patients.ConclusionsWith additional clinical experience, entrectinib continues to demonstrate durable systemic and intracranial responses and can address the unmet need of a CNS-active treatment in patients with NTRK fusion-positive solid tumors.

Published
2022

3. Supplementary Figure 2 from Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non–Small Cell Lung Cancer

Author

Mirhadi, Shideh, primary, Zhang, Wen, primary, Pham, Nhu-An, primary, Karimzadeh, Fereshteh, primary, Pintilie, Melania, primary, Tong, Jiefei, primary, Taylor, Paul, primary, Krieger, Jonathan, primary, Pitcher, Bethany, primary, Sykes, Jenna, primary, Wybenga-Groot, Leanne, primary, Fladd, Christopher, primary, Xu, Jing, primary, Wang, Tao, primary, Cabanero, Michael, primary, Li, Ming, primary, Weiss, Jessica, primary, Sakashita, Shingo, primary, Zaslaver, Olga, primary, Yu, Man, primary, Caudy, Amy A., primary, St-Pierre, Julie, primary, Hawkins, Cynthia, primary, Kislinger, Thomas, primary, Liu, Geoffrey, primary, Shepherd, Frances A., primary, Tsao, Ming-Sound, primary, and Moran, Michael F., primary

Published
2023
Full Text
View/download PDF

4. Supplementary Data from Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers

Author

Subbiah, Vivek, primary, Puzanov, Igor, primary, Blay, Jean-Yves, primary, Chau, Ian, primary, Lockhart, A. Craig, primary, Raje, Noopur S., primary, Wolf, Juergen, primary, Baselga, José, primary, Meric-Bernstam, Funda, primary, Roszik, Jason, primary, Diamond, Eli L., primary, Riely, Gregory J., primary, Sherman, Eric J., primary, Riehl, Todd, primary, Pitcher, Bethany, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

5. Supplementary Data 2 from Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non–Small Cell Lung Cancer

Author

Mirhadi, Shideh, primary, Zhang, Wen, primary, Pham, Nhu-An, primary, Karimzadeh, Fereshteh, primary, Pintilie, Melania, primary, Tong, Jiefei, primary, Taylor, Paul, primary, Krieger, Jonathan, primary, Pitcher, Bethany, primary, Sykes, Jenna, primary, Wybenga-Groot, Leanne, primary, Fladd, Christopher, primary, Xu, Jing, primary, Wang, Tao, primary, Cabanero, Michael, primary, Li, Ming, primary, Weiss, Jessica, primary, Sakashita, Shingo, primary, Zaslaver, Olga, primary, Yu, Man, primary, Caudy, Amy A., primary, St-Pierre, Julie, primary, Hawkins, Cynthia, primary, Kislinger, Thomas, primary, Liu, Geoffrey, primary, Shepherd, Frances A., primary, Tsao, Ming-Sound, primary, and Moran, Michael F., primary

Published
2023
Full Text
View/download PDF

6. Data from Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers

Author

Subbiah, Vivek, primary, Puzanov, Igor, primary, Blay, Jean-Yves, primary, Chau, Ian, primary, Lockhart, A. Craig, primary, Raje, Noopur S., primary, Wolf, Juergen, primary, Baselga, José, primary, Meric-Bernstam, Funda, primary, Roszik, Jason, primary, Diamond, Eli L., primary, Riely, Gregory J., primary, Sherman, Eric J., primary, Riehl, Todd, primary, Pitcher, Bethany, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

7. Table S1 from Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non–Small Cell Lung Cancer

Author

Mirhadi, Shideh, primary, Zhang, Wen, primary, Pham, Nhu-An, primary, Karimzadeh, Fereshteh, primary, Pintilie, Melania, primary, Tong, Jiefei, primary, Taylor, Paul, primary, Krieger, Jonathan, primary, Pitcher, Bethany, primary, Sykes, Jenna, primary, Wybenga-Groot, Leanne, primary, Fladd, Christopher, primary, Xu, Jing, primary, Wang, Tao, primary, Cabanero, Michael, primary, Li, Ming, primary, Weiss, Jessica, primary, Sakashita, Shingo, primary, Zaslaver, Olga, primary, Yu, Man, primary, Caudy, Amy A., primary, St-Pierre, Julie, primary, Hawkins, Cynthia, primary, Kislinger, Thomas, primary, Liu, Geoffrey, primary, Shepherd, Frances A., primary, Tsao, Ming-Sound, primary, and Moran, Michael F., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Data 1 from Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non–Small Cell Lung Cancer

Author

Mirhadi, Shideh, primary, Zhang, Wen, primary, Pham, Nhu-An, primary, Karimzadeh, Fereshteh, primary, Pintilie, Melania, primary, Tong, Jiefei, primary, Taylor, Paul, primary, Krieger, Jonathan, primary, Pitcher, Bethany, primary, Sykes, Jenna, primary, Wybenga-Groot, Leanne, primary, Fladd, Christopher, primary, Xu, Jing, primary, Wang, Tao, primary, Cabanero, Michael, primary, Li, Ming, primary, Weiss, Jessica, primary, Sakashita, Shingo, primary, Zaslaver, Olga, primary, Yu, Man, primary, Caudy, Amy A., primary, St-Pierre, Julie, primary, Hawkins, Cynthia, primary, Kislinger, Thomas, primary, Liu, Geoffrey, primary, Shepherd, Frances A., primary, Tsao, Ming-Sound, primary, and Moran, Michael F., primary

Published
2023
Full Text
View/download PDF

9. Data from Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non–Small Cell Lung Cancer

Author

Mirhadi, Shideh, primary, Zhang, Wen, primary, Pham, Nhu-An, primary, Karimzadeh, Fereshteh, primary, Pintilie, Melania, primary, Tong, Jiefei, primary, Taylor, Paul, primary, Krieger, Jonathan, primary, Pitcher, Bethany, primary, Sykes, Jenna, primary, Wybenga-Groot, Leanne, primary, Fladd, Christopher, primary, Xu, Jing, primary, Wang, Tao, primary, Cabanero, Michael, primary, Li, Ming, primary, Weiss, Jessica, primary, Sakashita, Shingo, primary, Zaslaver, Olga, primary, Yu, Man, primary, Caudy, Amy A., primary, St-Pierre, Julie, primary, Hawkins, Cynthia, primary, Kislinger, Thomas, primary, Liu, Geoffrey, primary, Shepherd, Frances A., primary, Tsao, Ming-Sound, primary, and Moran, Michael F., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 1 from Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non–Small Cell Lung Cancer

Author

Mirhadi, Shideh, primary, Zhang, Wen, primary, Pham, Nhu-An, primary, Karimzadeh, Fereshteh, primary, Pintilie, Melania, primary, Tong, Jiefei, primary, Taylor, Paul, primary, Krieger, Jonathan, primary, Pitcher, Bethany, primary, Sykes, Jenna, primary, Wybenga-Groot, Leanne, primary, Fladd, Christopher, primary, Xu, Jing, primary, Wang, Tao, primary, Cabanero, Michael, primary, Li, Ming, primary, Weiss, Jessica, primary, Sakashita, Shingo, primary, Zaslaver, Olga, primary, Yu, Man, primary, Caudy, Amy A., primary, St-Pierre, Julie, primary, Hawkins, Cynthia, primary, Kislinger, Thomas, primary, Liu, Geoffrey, primary, Shepherd, Frances A., primary, Tsao, Ming-Sound, primary, and Moran, Michael F., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table 1 from Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers

Author

Subbiah, Vivek, primary, Puzanov, Igor, primary, Blay, Jean-Yves, primary, Chau, Ian, primary, Lockhart, A. Craig, primary, Raje, Noopur S., primary, Wolf, Juergen, primary, Baselga, José, primary, Meric-Bernstam, Funda, primary, Roszik, Jason, primary, Diamond, Eli L., primary, Riely, Gregory J., primary, Sherman, Eric J., primary, Riehl, Todd, primary, Pitcher, Bethany, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Table 2 from Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers

Author

Subbiah, Vivek, primary, Puzanov, Igor, primary, Blay, Jean-Yves, primary, Chau, Ian, primary, Lockhart, A. Craig, primary, Raje, Noopur S., primary, Wolf, Juergen, primary, Baselga, José, primary, Meric-Bernstam, Funda, primary, Roszik, Jason, primary, Diamond, Eli L., primary, Riely, Gregory J., primary, Sherman, Eric J., primary, Riehl, Todd, primary, Pitcher, Bethany, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

13. protocol_2018.789990.pdf from Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers

Author

Subbiah, Vivek, primary, Puzanov, Igor, primary, Blay, Jean-Yves, primary, Chau, Ian, primary, Lockhart, A. Craig, primary, Raje, Noopur S., primary, Wolf, Juergen, primary, Baselga, José, primary, Meric-Bernstam, Funda, primary, Roszik, Jason, primary, Diamond, Eli L., primary, Riely, Gregory J., primary, Sherman, Eric J., primary, Riehl, Todd, primary, Pitcher, Bethany, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

14. Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer

Author

Goody, Rebecca B., MacKay, Helen, Pitcher, Bethany, Oza, Amit, Siu, Lillian L., Kim, John, Wong, Rebecca K.S., Chen, Eric, Swallow, Carol, Knox, Jennifer, Kassam, Zahra, Cummings, Bernard, Feld, Ron, Hedley, David, Liu, Geoffrey, Krzyzanowska, Monika K., Dinniwell, Robert, Brade, Anthony M., Dawson, Laura A., Pintilie, Melania, and Ringash, Jolie

Published
2016
Full Text
View/download PDF

15. Supplementary Materials from Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma

Author

Wu, Licun, primary, Allo, Ghassan, primary, John, Thomas, primary, Li, Ming, primary, Tagawa, Tetsuzo, primary, Opitz, Isabelle, primary, Anraku, Masaki, primary, Yun, Zhihong, primary, Pintilie, Melania, primary, Pitcher, Bethany, primary, Liu, Geoffrey, primary, Feld, Ron, primary, Johnston, Michael R., primary, de Perrot, Marc, primary, and Tsao, Ming-Sound, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

Author

Demetri, George D., primary, De Braud, Filippo, primary, Drilon, Alexander, primary, Siena, Salvatore, primary, Patel, Manish R., primary, Cho, Byoung Chul, primary, Liu, Stephen V., primary, Ahn, Myung-Ju, primary, Chiu, Chao-Hua, primary, Lin, Jessica J., primary, Goto, Koichi, primary, Lee, Jeeyun, primary, Bazhenova, Lyudmila, primary, John, Thomas, primary, Fakih, Marwan, primary, Chawla, Sant P., primary, Dziadziuszko, Rafal, primary, Seto, Takashi, primary, Heinzmann, Sebastian, primary, Pitcher, Bethany, primary, Chen, David, primary, Wilson, Timothy R., primary, and Rolfo, Christian, primary

Published
2023
Full Text
View/download PDF

17. Data from Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma

Author

Wu, Licun, primary, Allo, Ghassan, primary, John, Thomas, primary, Li, Ming, primary, Tagawa, Tetsuzo, primary, Opitz, Isabelle, primary, Anraku, Masaki, primary, Yun, Zhihong, primary, Pintilie, Melania, primary, Pitcher, Bethany, primary, Liu, Geoffrey, primary, Feld, Ron, primary, Johnston, Michael R., primary, de Perrot, Marc, primary, and Tsao, Ming-Sound, primary

Published
2023
Full Text
View/download PDF

18. Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non–Small Cell Lung Cancer

Author

Mirhadi, Shideh, primary, Zhang, Wen, additional, Pham, Nhu-An, additional, Karimzadeh, Fereshteh, additional, Pintilie, Melania, additional, Tong, Jiefei, additional, Taylor, Paul, additional, Krieger, Jonathan, additional, Pitcher, Bethany, additional, Sykes, Jenna, additional, Wybenga-Groot, Leanne, additional, Fladd, Christopher, additional, Xu, Jing, additional, Wang, Tao, additional, Cabanero, Michael, additional, Li, Ming, additional, Weiss, Jessica, additional, Sakashita, Shingo, additional, Zaslaver, Olga, additional, Yu, Man, additional, Caudy, Amy A., additional, St-Pierre, Julie, additional, Hawkins, Cynthia, additional, Kislinger, Thomas, additional, Liu, Geoffrey, additional, Shepherd, Frances A., additional, Tsao, Ming-Sound, additional, and Moran, Michael F., additional

Published
2022
Full Text
View/download PDF

19. Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study

Author

Diamond, Eli L., Subbiah, Vivek, Lockhart, A. Craig, Blay, Jean-Yves, Puzanov, Igor, Chau, Ian, Raje, Noopur S., Wolf, Jurgen, Erinjeri, Joseph P., Torrisi, Jean, Lacouture, Mario, Elez, Elena, Martínez-Valle, Ferran, Durham, Benjamin, Arcila, Maria E., Ulaner, Gary, Abdel-Wahab, Omar, Pitcher, Bethany, Makrutzki, Martina, Riehl, Todd, Baselga, José, and Hyman, David M.

Published
2018
Full Text
View/download PDF

21. Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.

Author

Krzakowski, Maciej Jerzy, primary, Lu, Shun, additional, Cousin, Sophie, additional, Smit, Egbert F., additional, Springfeld, Christoph, additional, Goto, Koichi, additional, Garrido, Pilar, additional, Chung, Christine H., additional, Lin, Jessica Jiyeong, additional, Bray, Victoria J., additional, Pitcher, Bethany, additional, Zeuner, Harald, additional, Patel, Siddhartha, additional, Bordogna, Walter, additional, and Gelderblom, Hans, additional

Published
2022
Full Text
View/download PDF

22. Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

Author

Drilon, Alexander, primary, Chiu, Chao-Hua, additional, Fan, Yun, additional, Cho, Byoung Chul, additional, Lu, Shun, additional, Ahn, Myung-Ju, additional, Krebs, Matthew G., additional, Liu, Stephen V., additional, John, Thomas, additional, Otterson, Gregory A., additional, Tan, Daniel S.W., additional, Patil, Tejas, additional, Dziadziuszko, Rafal, additional, Massarelli, Erminia, additional, Seto, Takashi, additional, Doebele, Robert C., additional, Pitcher, Bethany, additional, Kurtsikidze, Nino, additional, Heinzmann, Sebastian, additional, and Siena, Salvatore, additional

Published
2022
Full Text
View/download PDF

23. Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors

Author

Demetri, George D., primary, De Braud, Filippo, additional, Drilon, Alexander, additional, Siena, Salvatore, additional, Patel, Manish R., additional, Cho, Byoung Chul, additional, Liu, Stephen V., additional, Ahn, Myung-Ju, additional, Chiu, Chao-Hua, additional, Lin, Jessica J., additional, Goto, Koichi, additional, Lee, Jeeyun, additional, Bazhenova, Lyudmila, additional, John, Thomas, additional, Fakih, Marwan, additional, Chawla, Sant P., additional, Dziadziuszko, Rafal, additional, Seto, Takashi, additional, Heinzmann, Sebastian, additional, Pitcher, Bethany, additional, Chen, David, additional, Wilson, Timothy R., additional, and Rolfo, Christian, additional

Published
2022
Full Text
View/download PDF

24. Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.

Author

Rolfo, Christian Diego, primary, De Braud, Filippo G., additional, Doebele, Robert Charles, additional, Drilon, Alexander E., additional, Siena, Salvatore, additional, Patel, Manish, additional, Cho, Byoung Chul, additional, Liu, Stephen V., additional, Ahn, Myung-Ju, additional, Chiu, Chao-Hua, additional, Farago, Anna F., additional, Goto, Koichi, additional, Lee, Jeeyun, additional, Bazhenova, Lyudmila, additional, John, Tom, additional, Fakih, Marwan, additional, Simmons, Brian P., additional, Pitcher, Bethany, additional, Huang, Xinhui, additional, and Demetri, George D., additional

Published
2020
Full Text
View/download PDF

25. Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers

Author

Subbiah, Vivek, primary, Puzanov, Igor, additional, Blay, Jean-Yves, additional, Chau, Ian, additional, Lockhart, A. Craig, additional, Raje, Noopur S., additional, Wolf, Juergen, additional, Baselga, José, additional, Meric-Bernstam, Funda, additional, Roszik, Jason, additional, Diamond, Eli L., additional, Riely, Gregory J., additional, Sherman, Eric J., additional, Riehl, Todd, additional, Pitcher, Bethany, additional, and Hyman, David M., additional

Published
2020
Full Text
View/download PDF

26. Efficacy of Vemurafenib in Patients With Non–Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study

Author

Subbiah, Vivek, primary, Gervais, Radj, additional, Riely, Gregory, additional, Hollebecque, Antoine, additional, Blay, Jean-Yves, additional, Felip, Enriqueta, additional, Schuler, Martin, additional, Gonçalves, Anthony, additional, Italiano, Antonio, additional, Keedy, Vicki, additional, Chau, Ian, additional, Puzanov, Igor, additional, Raje, Noopur S., additional, Meric-Bernstam, Funda, additional, Makrutzki, Martina, additional, Riehl, Todd, additional, Pitcher, Bethany, additional, Baselga, Jose, additional, and Hyman, David M., additional

Published
2019
Full Text
View/download PDF

27. BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study

Author

Kaley, Thomas, primary, Touat, Mehdi, additional, Subbiah, Vivek, additional, Hollebecque, Antoine, additional, Rodon, Jordi, additional, Lockhart, A. Craig, additional, Keedy, Vicki, additional, Bielle, Franck, additional, Hofheinz, Ralf-Dieter, additional, Joly, Florence, additional, Blay, Jean-Yves, additional, Chau, Ian, additional, Puzanov, Igor, additional, Raje, Noopur S., additional, Wolf, Jurgen, additional, DeAngelis, Lisa M., additional, Makrutzki, Martina, additional, Riehl, Todd, additional, Pitcher, Bethany, additional, Baselga, Jose, additional, and Hyman, David M., additional

Published
2018
Full Text
View/download PDF

28. Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-BASKET Study

Author

Raje, Noopur, primary, Chau, Ian, additional, Hyman, David M., additional, Ribrag, Vincent, additional, Blay, Jean-Yves, additional, Tabernero, Josep, additional, Elez, Elena, additional, Wolf, Jürgen, additional, Yee, Andrew J., additional, Kaiser, Martin, additional, Landau, Heather, additional, Michot, Jean-Marie, additional, Hollebecque, Antoine, additional, Veronese, Luisa, additional, Makrutzki, Martina, additional, Pitcher, Bethany, additional, Puzanov, Igor, additional, and Baselga, Jose, additional

Published
2018
Full Text
View/download PDF

29. A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).

Author

Bendell, Johanna C., primary, Bang, Yung-Jue, additional, Chee, Cheng Ean, additional, Ryan, David P., additional, McRee, Autumn Jackson, additional, Chow, Laura Q., additional, Desai, Jayesh, additional, Wongchenko, Matthew, additional, Yan, Yibing, additional, Pitcher, Bethany, additional, Foster, Paul, additional, Cha, Edward, additional, Grossman, William, additional, and Kim, Tae Won, additional

Published
2018
Full Text
View/download PDF

30. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)

Author

Labbé, Catherine, primary, Cabanero, Michael, additional, Korpanty, Grzegorz J., additional, Tomasini, Pascale, additional, Doherty, Mark K., additional, Mascaux, Céline, additional, Jao, Kevin, additional, Pitcher, Bethany, additional, Wang, Rick, additional, Pintilie, Melania, additional, Leighl, Natasha B., additional, Feld, Ronald, additional, Liu, Geoffrey, additional, Bradbury, Penelope Ann, additional, Kamel-Reid, Suzanne, additional, Tsao, Ming-Sound, additional, and Shepherd, Frances A., additional

Published
2017
Full Text
View/download PDF

31. Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.

Author

Sullivan, Ryan J., primary, Gonzalez, Rene, additional, Lewis, Karl D., additional, Hamid, Omid, additional, Infante, Jeffrey R., additional, Patel, Manish R., additional, Hodi, F. Stephen, additional, Wallin, Jeffrey, additional, Pitcher, Bethany, additional, Cha, Edward, additional, Roberts, Louise, additional, Ballinger, Marcus, additional, and Hwu, Patrick, additional

Published
2017
Full Text
View/download PDF

33. Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study.

Author

Hyman, David Michael, primary, Kaley, Thomas Joseph, additional, Hollebecque, Antoine, additional, Subbiah, Vivek, additional, Rodon Ahnert, Jordi, additional, Lockhart, A. Craig, additional, Keedy, Vicki Leigh, additional, Hofheinz, Ralf, additional, Joly Lobbedez, Florence, additional, Blay, Jean-Yves, additional, Chau, Ian, additional, Puzanov, Igor, additional, Raje, Noopur, additional, Wolf, Juergen, additional, Makrutzki, Martina, additional, Riehl, Todd, additional, Pitcher, Bethany, additional, and Baselga, Jose, additional

Published
2017
Full Text
View/download PDF

34. Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation.

Author

Subbiah, Vivek, primary, Gervais, Radj, additional, Riely, Gregory J., additional, Hollebecque, Antoine, additional, Blay, Jean-Yves, additional, Felip, Enriqueta, additional, Schuler, Martin H., additional, Goncalves, Anthony, additional, Italiano, Antoine, additional, Keedy, Vicki Leigh, additional, Chau, Ian, additional, Puzanov, Igor, additional, Raje, Noopur, additional, Makrutzki, Martina, additional, Riehl, Todd, additional, Pitcher, Bethany, additional, Hyman, David Michael, additional, and Baselga, Jose, additional

Published
2017
Full Text
View/download PDF

35. Radiation Therapy Patient Experience Survey of Early-Stage Breast Cancer Women

Author

Lee, Grace, primary, Dinniwell, Robert, additional, Fyles, Anthony, additional, Conrad, Tatiana, additional, Han, Kathy, additional, Levin, Wilfred, additional, Liu, Fei-Fei, additional, Lofgren, Susanne, additional, Devins, Gerald, additional, Emad, Nora, additional, Koch-Fitsialos, Alexandra, additional, Pitcher, Bethany, additional, Panzarella, Tony, additional, and Koch, Anne, additional

Published
2017
Full Text
View/download PDF

36. Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma

Author

Wu, Licun, primary, Allo, Ghassan, additional, John, Thomas, additional, Li, Ming, additional, Tagawa, Tetsuzo, additional, Opitz, Isabelle, additional, Anraku, Masaki, additional, Yun, Zhihong, additional, Pintilie, Melania, additional, Pitcher, Bethany, additional, Liu, Geoffrey, additional, Feld, Ron, additional, Johnston, Michael R., additional, de Perrot, Marc, additional, and Tsao, Ming-Sound, additional

Published
2017
Full Text
View/download PDF

38. PUB052 Proteome Signatures and New Cancer Drivers

Author

Zhang, Wen, primary, Sakashita, Shingo, additional, Pintilie, Melania, additional, Pitcher, Bethany, additional, Tong, Jiefei, additional, Taylor, Paul, additional, Pham, Nhu-An, additional, Li, Ming, additional, Wang, Tao, additional, Cabanero, Michael, additional, Tsao, Ming, additional, and Moran, Michael, additional

Published
2017
Full Text
View/download PDF

40. MATE2 Expression Is Associated with Cancer Cell Response to Metformin

Author

Chowdhury, Sanjana, primary, Yung, Eric, additional, Pintilie, Melania, additional, Muaddi, Hala, additional, Chaib, Selim, additional, Yeung, ManTek, additional, Fusciello, Manlio, additional, Sykes, Jenna, additional, Pitcher, Bethany, additional, Hagenkort, Anna, additional, McKee, Trevor, additional, Vellanki, Ravi, additional, Chen, Eric, additional, Bristow, Robert G., additional, Wouters, Bradly G., additional, and Koritzinsky, Marianne, additional

Published
2016
Full Text
View/download PDF

41. BRAF Inhibition in V600-Mutant Gliomas: Results From the VE-BASKET Study.

Author

Kaley, Thomas, Touat, Mehdi, Subbiah, Vivek, Hollebecque, Antoine, Rodon, Jordi, Lockhart, A. Craig, Keedy, Vicki, Bielle, Franck, Hofheinz, Ralf-Dieter, Joly, Florence, Blay, Jean-Yves, Chau, Ian, Puzanov, Igor, Raje, Noopur S., Wolf, Jurgen, DeAngelis, Lisa M., Makrutzki, Martina, Riehl, Todd, Pitcher, Bethany, and Baselga, Jose

Published
2018
Full Text
View/download PDF

42. Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis

Author

Deotare, Uday, primary, Shaheen, Marwan, additional, Brandwein, Joseph M., additional, Pitcher, Bethany, additional, Kamel-Reid, Suzanne, additional, Yee, Karen W.L., additional, Schimmer, Aaron, additional, Minden, Mark D., additional, Gupta, Vikas, additional, and Schuh, Andre C., additional

Published
2016
Full Text
View/download PDF

43. 181: Patient Experience Survey of Early-Stage Breast Cancer Patients Undergoing Whole Breast Radiotherapy

Author

Lee, Grace, primary, Dinniwell, Robert, additional, Fyles, Anthony, additional, Conrad, Tatiana, additional, Han, Kathy, additional, Levin, Wilfred, additional, Liu, Fei-Fei, additional, Lofgren, Susanne, additional, Koch-Fitsialos, Alexandra, additional, Devins, Gerald, additional, Emad, Nora, additional, Pitcher, Bethany, additional, Panzarella, Tony, additional, and Koch, Anne, additional

Published
2016
Full Text
View/download PDF

44. Prognostic and predictive effects of TP53 mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).

Author

Labbe, Catherine, primary, Korpanty, Grzegorz, additional, Tomasini, Pascale, additional, Doherty, Mark, additional, Mascaux, Celine, additional, Jao, Kevin, additional, Pitcher, Bethany, additional, Pintilie, Melania, additional, Leighl, Natasha B., additional, Feld, Ronald, additional, Liu, Geoffrey, additional, Bradbury, Penelope Ann, additional, Kamel-Reid, Suzanne, additional, Tsao, Ming Sound, additional, and Shepherd, Frances A., additional

Published
2016
Full Text
View/download PDF

45. Smoking status and treatment outcome in patients with pancreatic cancer.

Author

Korpanty, Grzegorz, primary, Dodd, Anna, additional, McGrath, Evelyn, additional, Pitcher, Bethany, additional, Borgida, Ayelet, additional, Holter, Spring, additional, Dhani, Neesha C., additional, Hedley, David W., additional, Gallinger, Steven, additional, Cleary, Sean P., additional, Greig, Paul D, additional, McGilvray, Ian M, additional, Moulton, Carol-Anne, additional, Wei, Alice Chia-chi, additional, Brierley, James D., additional, Dawson, Laura A., additional, Kim, John, additional, and Moore, Malcolm J., additional

Published
2016
Full Text
View/download PDF

46. Prospective evaluation of quality of life (QOL) during a phase I/II study of adjuvant chemotherapy with image-guided high-precision radiotherapy for completely resected gastric cancer.

Author

Goody, Rebecca Barbara, primary, Mackay, Helen, additional, Pitcher, Bethany, additional, Oza, Amit M., additional, Brierley, James D., additional, Kim, Joon-Hyung J., additional, Wong, Rebecca, additional, Kassam, Zahra, additional, Swallow, Carol Jane, additional, Cummings, Bernard, additional, Dinniwell, Robert Edward, additional, Knox, Jennifer J., additional, Brade, Anthony M., additional, Dawson, Laura A., additional, Pintilie, Melania, additional, and Ringash, Jolie, additional

Published
2016
Full Text
View/download PDF

47. A proposal for cellularity assessment for EGFR mutational analysis with a correlation with DNA yield and evaluation of the number of sections obtained from cell blocks for immunohistochemistry in non-small cell lung carcinoma

Author

da Cunha Santos, Gilda, primary, Wyeth, Tyler, additional, Reid, Allie, additional, Saieg, Mauro Ajaj, additional, Pitcher, Bethany, additional, Pintilie, Melania, additional, Kamel-Reid, Suzanne, additional, and Tsao, Ming Sound, additional

Published
2016
Full Text
View/download PDF

48. Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis.

Author

Deotare, Uday, Shaheen, Marwan, Brandwein, Joseph M., Pitcher, Bethany, Kamel‐Reid, Suzanne, Yee, Karen W.L., Schimmer, Aaron, Minden, Mark D., Gupta, Vikas, and Schuh, Andre C.

Abstract

We analyzed the outcome of 80 sequential patients with core binding factor acute myeloid leukemia and evaluated the influence of molecular monitoring by quantitative reverse transcriptase polymerase chain reaction. With a median follow-up of 5 years, the estimated 5-year relapse-free survival and overall survival were 58% and 66%, respectively. Patients who were in molecular remission at the completion of consolidation chemotherapy had a 21% risk of relapse, while the relapse risk for those in molecular remission at the end of 2 years was 5.5%. Our data indicate that postconsolidation molecular remission does not necessarily preclude disease relapse and further monitoring is required. In contrast, molecular negativity by quantitative reverse transcriptase polymerase chain reaction at the end of 2 years is associated with a low risk of relapse. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

49. Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors

Author

Krzakowski, Maciej Jerzy, Lu, Shun, Cousin, Sophie, Smit, Egbert F., Springfeld, Christoph, Goto, Koichi, Garrido, Pilar, Chung, Christine H., Jessica Lin, Bray, Victoria J., Pitcher, Bethany, Zeuner, Harald, Patel, Siddhartha, Bordogna, Walter, and Gelderblom, Hans

Subjects
Cancer Research, Oncology
Abstract

3099 Background: NTRK gene fusions, coding for chimeric TRK proteins, are oncogenic drivers in many solid tumors. In an integrated analysis of three phase 1/2 trials (ALKA-372-001 [EudraCT 2012-000148-88]; STARTRK-1 [NCT02097810]; STARTRK-2 [NCT02568267]), entrectinib, a potent CNS-active TRK inhibitor, showed durable systemic and intracranial responses in pts with NTRK-fp solid tumors. We report updated data from a larger cohort with longer follow-up (clinical cutoff 2 Aug 2021). Methods: Pts with locally advanced/metastatic NTRK-fp solid tumors and ≥12 months’ follow-up from first tumor assessment were efficacy evaluable. The safety cohort also included pts from TAPISTRY (NCT04589845). Tumor responses were assessed by blinded independent central review (BICR) per RECIST v1.1 at Week 4 and every 8 weeks thereafter. Primary endpoints: objective response rate (ORR) and duration of response (DoR). Progression-free survival (PFS), overall survival (OS), intracranial (IC)-ORR and safety were also assessed. Results: The efficacy-evaluable cohort comprised 150 adults (vs 121 previously) with 17 different solid tumor types. Median age was 58.5 years; 91% of pts had ECOG PS 0–1 and 37% had received ≥2 prior lines of therapy. Median survival follow-up was 30.6 months. ORR was 61.3% (n = 92/150; 95% CI: 53.1–69.2), including 25 complete responses. Responses were observed in all tumor types with n>1 (Table). Median DoR, PFS and OS were 20.0 months (95% CI 13.2–31.1), 13.8 months (95% CI 10.1–20.0), and 37.1 months (95% CI 27.2–not estimable [NE]), respectively. In pts with and without investigator-assessed baseline CNS metastases (n = 31 / n = 119), ORR was 61.3% (95% CI 42.2–78.2) and 61.3% (95% CI 52.0–70.1) respectively. IC-ORR was 69.2% (n = 9/13) in pts with BICR-assessed measurable CNS metastases; median IC-DoR was 17.2 months (7.4–NE). In the safety population (N = 235: all treated pts), most treatment-related adverse events (TRAEs) were grade 1/2 and not serious; the most frequent were dysgeusia (36.6%), diarrhea (29.8%) and weight increase (28.5%). TRAEs led to dose interruption, reduction and discontinuation in 32.8%, 24.3% and 7.2% of pts, respectively. Conclusions: In this updated analysis, entrectinib continued to demonstrate deep and durable responses and was well tolerated in pts with NTRK-fp solid tumors with or without baseline CNS metastases. Clinical trial information: STARTRK-2 [NCT02568267]. [Table: see text]

50. Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non-Small Cell Lung Cancer.

Author

Mirhadi S, Zhang W, Pham NA, Karimzadeh F, Pintilie M, Tong J, Taylor P, Krieger J, Pitcher B, Sykes J, Wybenga-Groot L, Fladd C, Xu J, Wang T, Cabanero M, Li M, Weiss J, Sakashita S, Zaslaver O, Yu M, Caudy AA, St-Pierre J, Hawkins C, Kislinger T, Liu G, Shepherd FA, Tsao MS, and Moran MF

Subjects
Mice, Animals, Iron metabolism, Aconitate Hydratase genetics, Aconitate Hydratase metabolism, Homeostasis, Membrane Proteins metabolism, Iron-Binding Proteins, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms genetics
Abstract

The ability of a patient tumor to engraft an immunodeficient mouse is the strongest known independent indicator of poor prognosis in early-stage non-small cell lung cancer (NSCLC). Analysis of primary NSCLC proteomes revealed low-level expression of mitochondrial aconitase (ACO2) in the more aggressive, engrafting tumors. Knockdown of ACO2 protein expression transformed immortalized lung epithelial cells, whereas upregulation of ACO2 in transformed NSCLC cells inhibited cell proliferation in vitro and tumor growth in vivo. High level ACO2 increased iron response element binding protein 1 (IRP1) and the intracellular labile iron pool. Impaired cellular proliferation associated with high level ACO2 was reversed by treatment of cells with an iron chelator, whereas increased cell proliferation associated with low level ACO2 was suppressed by treatment of cells with iron. Expression of CDGSH iron-sulfur (FeS) domain-containing protein 1 [CISD1; also known as mitoNEET (mNT)] was modulated by ACO2 expression level and inhibition of mNT by RNA interference or by treatment of cells with pioglitazone also increased iron and cell death. Hence, ACO2 is identified as a regulator of iron homeostasis and mNT is implicated as a target in aggressive NSCLC., Implications: FeS cluster-associated proteins including ACO2, mNT (encoded by CISD1), and IRP1 (encoded by ACO1) are part of an "ACO2-Iron Axis" that regulates iron homeostasis and is a determinant of a particularly aggressive subset of NSCLC., (©2022 The Authors; Published by the American Association for Cancer Research.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results